Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
News|Videos|January 21, 2025 (Updated: February 14, 2025)
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Author(s)Sarah Sammons, MD
Sarah Sammons, MD, highlights ReDiscover trial findings, showcasing the durable efficacy, potent mutant-selective targeting, and favorable safety profile of RLY-2608 combined with fulvestrant in patients with PIK3CA-mutant HR+/HER2− advanced breast cancer, validating its potential as the first allosteric, pan-mutant PI3Kα inhibitor.
Advertisement
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
4
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
5